despite the strong unbilled figure, its cost management is not convincing. GP is fluctuating.

benefit from the up coming e-invoicing.

Cap A need RM10bil to be uplifted from PN17. That is the cost AAX has to bear if AAX acquires the aviation biz. Does it worth RM10bil? Tough job!

TAS is on the right track of recovering from its glory days.

plenty of speculative plays here

uplifting fr PN17 is still pending..... not a good sign.

Cansino share price is at historical low......

yes, waited long for the market to revalue this counter. Somehow it is very sensitive to the fluctuation of international oil prices.

for sure, this counter is under valued. the share base is too big.

local demand is recovering. buy and hold. no short term play.

The power of patience is always rewarded. Fundamentally AAX is sound. AAX is still under valued.
The inclusion of AA to AAX is a matter of valuation. Don't think Tony wants to kill AAX.

the last exercise now is the rights issue and special issue, expected to be completed within the next few months. uplifting from PN17 is just a matter of time. aviation and logistics industry are recovering well. with a clean balance sheet, AAX should perform well in coming quarters.

I think the market is over reacted. cypark is basically an infra/concession company, its business nature is capital intensive. it requires upfront investment and gets back the cash over 20+ years. i see such drop as an opportunity to collect.

it is a "clean" company now. good recovery stock to consider.

this is the cheapest bank you can get. 2022 is a much better year for Malaysian banks.

Penta HK is a better pick.

one off gain. one day show :(

This is capital intensive business. MCOs caused multiple delays in completing WTE, LSS2 & 3. And such delays added more cost to the projects. Nevertheless, as many said, they are now at "last mile" to complete and commission these projects. Their cashflows will improve from thereon. The current valuation is attractive. Expect to have a very good year 2022 for Cypark.

must hold a bit longer as they are ready to achieve for good results from next year onwards.

tough time. not easy for 0200. but judging from its valuation, latest qr and foreseeable performance in near future, 0200 is not cheap. perhaps that's why major shareholder sold while the price was high.

as mentioned in its qr, upsides are less attractive now. ultimately I think they will quit the dry bulk business with very healthy balance sheet.

well managed company with strong fundamentals. valuation is relatively low. but market worries whether or not the CPO price is sustainable & esg concerns. is plantation sector experiencing major re-rating (down)?

almost all the malaysia banks are making good profit. share prices are attractive too.

low profile company. I think the Koreans have done a good job in restructuring the entire group and disposed the loss making courier business. healthy cash flow and balance sheet. all other segments are profit making. expect to see FY2022 in black with good support from CJ Group as a whole. valuation now is attractive.

dont purely look at one or two qr. the performance of QES expect to grow significantly by next year onwards. current valuation is not expensive in long run. hold it as long as you can. they are moving in right direction and partner with the right ppl.

95.4% of our adult population are fully vaccinated. the primary vaccine market here is getting smaller. missed a few times on GMP target dates, it shows their inexperience in F&F. the approved combinations now are SSP, SSS, PPP, AAA. CanSino still not in booster dose list and not for adolescents too. after the introduction of SSP, locals seem prefer homologous. Without WHO granting the emergency use (and you hv yet to obtain GMP), overseas market expect to be challenging. further, Cansino is less known in the market too. 0093 started this vaccine venture one of the earliest last year but now they are behind everyone. many of us follow from day one, was excited and bought this counter last year and had high hope but the reality is they fail to deliver and compete. Now, how do they move forward? to achieve financial sustainability in years ahead, perhaps they may have to think beyond covid vaccine.

congratulations @YOLOorLOL for making big money. looks like you are the boss or the man behind the boss. newcomer like me should follow you ya.

aiyo, if gv 20 sen fattatt liao... rm25mil translates to eps of only RM0.057/share. oh betul.... they may issue more esos to increase the major shareholders' %

we may have to examine their past m&a, especially on its profit guaranteed. overall profit growth does not in line with more acquisitions. can we see their future? where are the business?

very disappointed results. need a lot more political will and courage to totally revamp POS.

刮大风时别去扫树叶。。。。

renewable energy is definitely the future. Cypark business model is inclusive and capital intensive. with good management, be it financial or business, the company shall perform well in the future.

I believe in fundamentals and value. hope to see good QR. wishing all PFI shareholders best of luck.

with 3.5m doses fully delivered, plus other businesses, 0093 is expected to achieve not less than RM25mil nat for fy2021. they may reward the shareholders half of their earnings. this is extremely good. but the biggest challenge is: sustainability.

to be precise, 76.1% of the total population are fully vaccinated. the balance of 23.9% includes children below 12 yo. So, still got chance? undocumented migrants? pretty tough, right? plenty of doses still in KKM store rooms. Cansino booster shot has sufficient real world data?

despite all the problems, isn't it over sold?

agree with @Jeffbkt. anyway, this is a good buying opportunity.

i don't see any fundamental change. let's wait for the QR.

betul juga...... tak ada niaga vax baru buat lah niaga goreng!

dont tell me the bosses dont know it was planned.

delivered 2.6mil, only administered <200,000 doses since Aug'21. plenty of FREE Cansino vax with KKM, who want to buy from private? 90.2% of our population are fully vaxed ..... domestic market is getting smaller and smaller. If ppl hesitate to take Pfizer or Sinovac as booster dose, do they choose Cansino (no WHO approval)? don't see any financial value from last night announcement. btw, what happen to yr GMP and ASEAN market?

hidden gem.

golden opportunity is gone. no one bother the 3.5m doses vax that not recognise by WHO anymore. so, how much this counter worth now? 20 sen?

it seems the company is undergoing a major business restructuring, gradually disposing all its ships. plan to venture into new business in the future?

fundamentals are improving. its valuation is much higher than the existing share price. must be able to hold for a year or two.

no hope, must change mind fast lor. no news, no announcement, no experience, no idea the progress...... really difficult counter.

thanks @daijiao for the infor. no stock no hope. back to 20 sen soon?

right biz + right ppl. well managed, strong balance sheet. base on projected forward earnings, the current valuation is not expensive.

steel prices is coming down from its peak. this is a fact.

please read the announcement carefully. it is sales contract follow by a mou......dont be too excited.